Department of Surgery and Center for Minimally Invasive Surgery, Academic Teaching Hospital of Charité Medical School, Vivantes Hospital, Neue Bergstrasse 6, Berlin, Germany.
Department of General and Visceral Surgery, GRN-Hospital Weinheim, Röntgenstrasse 1, Weinheim, Germany.
Ann Surg. 2018 Dec;268(6):1097-1104. doi: 10.1097/SLA.0000000000002326.
To assess the role of registries in the postmarketing surveillance of surgical meshes.
To date, surgical meshes are classified as group II medical devices. Class II devices do not require premarket clearance by clinical studies. Ethicon initiated a voluntary market withdrawal of Physiomesh for laparoscopic use after an analysis of unpublished data from the 2 large independent hernia registries-Herniamed German Registry and Danish Hernia Database. This paper now presents the relevant data from the Herniamed Registry.
The present analysis compares the prospective perioperative and 1-year follow-up data collected for all patients with incisional hernia who had undergone elective laparoscopic intraperitoneal onlay mesh repair either with Physiomesh (n = 1380) or with other meshes recommended in the guidelines (n = 3834).
Patients with Physiomesh repair had a markedly higher recurrence rate compared with the other recommended meshes (12.0% vs 5.0%; P < 0.001). In the multivariable analysis, the recurrence rate was highly significantly influenced by the mesh type used (P < 0.001). If Physiomesh was used, that led to a highly significant increase in the recurrence rate on 1-year follow-up (odds ratio 2.570, 95% CI 2.057, 3.210). The mesh type used also had a significant influence on chronic pain rates.
The importance of real-world data for postmarketing surveillance of surgical meshes has been demonstrated in this registry-based study. Randomized controlled trials are needed for premarket approval of new devices. The role of sponsorship of device studies by the manufacturing company must be taken into account.
评估注册系统在外科补片的上市后监测中的作用。
迄今为止,外科补片被归类为 II 类医疗器械。II 类器械不需要通过临床研究获得上市前批准。在对来自 2 个大型独立疝注册中心(德国疝注册中心和丹麦疝数据库)的未发表数据进行分析后,Ethicon 主动对用于腹腔镜的 Physiomesh 进行了自愿市场撤出。本文现在呈现来自 Herniamed 注册中心的相关数据。
本分析比较了接受择期腹腔镜腹腔内补片修补术的所有切口疝患者的前瞻性围手术期和 1 年随访数据,这些患者使用 Physiomesh(n = 1380)或其他指南推荐的补片(n = 3834)。
使用 Physiomesh 修复的患者复发率明显高于其他推荐的补片(12.0%比 5.0%;P < 0.001)。在多变量分析中,使用的补片类型对复发率有显著影响(P < 0.001)。如果使用 Physiomesh,则 1 年随访时的复发率显著增加(优势比 2.570,95%置信区间 2.057,3.210)。使用的补片类型也对慢性疼痛发生率有显著影响。
这项基于注册的研究证明了真实世界数据在外科补片上市后监测中的重要性。新设备的上市前批准需要进行随机对照试验。必须考虑到制造公司赞助设备研究的作用。